Compare · NVO vs ONTX

NVO vs ONTX

Side-by-side comparison of Novo Nordisk A/S (NVO) and Onconova Therapeutics Inc. (ONTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and ONTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO carries a market cap of $180.22B.
  • NVO has hit the wire 9 times in the past 4 weeks while ONTX has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 1 for ONTX).
MetricNVOONTX
Company
Novo Nordisk A/S
Onconova Therapeutics Inc.
Price
-
-
Market cap
$180.22B
-
1M return
+5.96%
-
1Y return
-14.37%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2013
News (4w)
9
0
Recent ratings
25
1
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

ONTX

Onconova Therapeutics Inc.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.